Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nope!
fs
NEWS!
NEWS!
LoL!
That may well be true FDA and I know how that story ended however....
The hare didn't have rocket boosters that are not likely to run out any time soon!!!
Pluristem must respond. We need them to respond or we will be marginalised.
True and also.....
Hi Melon...
Quite so....
The question now is are Pluristem near enough to commercialisation to get the jump on Celularity, given the vast resources that are backing the new Celgene spin-off?
Will Pluristem respond to the threat this poses and if so, how?
Does anyone believe that this spin-off company has come into being from
Pluristems refusal to be either bought out or merge with one of the BIG P companies?
Please discuss if you will, without resorting to insults or hubris, remembering to be courteous to your fellow posters, whether you agree with their views or not.
GLTA
n3m
Perhaps Pluristem should have got a partner after all or....... if you cant join em, beat em!
Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack Cancer
Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
Shai Gozani just Bought 1,500 shares of NeuroMetrix, Inc. (NURO), be careful if you are short!
Source
Still more insider buys......
President/CEO.
I have added more and will keep on adding while insiders are putting more skin in the game. They know something is up.
Letter from Our Chairman
NICE backs EUSA's RCC treatment Fotivda
The UK’s cost-effectiveness watchdog recommends its first-line use.
UK Funding Approval
It should go up.....
It really depends on volume I reckon and how well the news is received.
NEWS!!!
Pluristem - Hidden Treasures And Sudden Catalysts
The article below lays out the case for Pluristem, benefit and risk perfectly without rose-coloured glasses.
excerpt from the article....(link to the full article below)
Something is up.....
There has been a string of insider buys of late (13 since 1/26/2018-2/06/2018).
Small amounts to be sure (perhaps not to draw too much attention) but it tells me that the CEO, CFO and other insiders are quietly confident, that something is going to happen to increase the value of those shares, in the not too distant future.
I have taken a small position here and may well increase it if any more insider buys start coming in.
GLTA
Pluristem Issues Letter to Shareholders
Scott,
The thing that worries me most from the 10Q is that they are saying they do not expect to sell anything in the next 12 months.
Now either they are being conservative with their estimate, as I believe PLX R18 will be sold this year to the US Gov, or they know something we dont and are not telling us. If they are being conservative it can only be to give the company profile (and pps) a big lift when a stockpiling contract is announced as it surely would, together with the other nations that would also want the ARS product as soon as the US Gov buy it.
The situation with North Korea will accelerate that if tensions get any higher, I think.
Money to run until 4Q 2019 is fine.... a lot can happen in that time period.
The other thing I took from the latest 10Q was:-
a) The expectation of revenues from licensing of PSTI assests.
b) The increased talk of licensing period, with only one mention of going it alone.
Pluristem seem to be coming to the conclusion, that in order to progress on as many front for as many indications that they are targeting they will have to do a licensing deal or deals. They need to get at least one product out there.
The language contained in the 10Q shows a clear realisation of this, therefore I wait to see exactly what action they will take, as regards licensing/partnering out PSTI technology in order to achieve a saleable product and further revenue.
Just my honest opinion.
GLTA
Redstar Engages Mine Development Associates to Complete a Technical Report at the Unga Gold Project
Redstar Gold engages MDA
Pluristem Status Report!! Edison: Due to the publication of reports, an increase in the valuation to $ 202 million
Sadly, I do not think so. PSTI (Pluristem on the NASDaq) suffers the same way. It's as if they have to report 50 times better than other biotechs to really move.
In PSTI's case they have over 100 patents protecting their IP and have turned down buyout offers out of hand. Its really sad
Hi King,
It's not the first time either. Check your pm
Rexahn Pharmaceuticals' RX-3117 could be a blockbuster, says HC Wainwright
Rexahn Pharmaceuticals RX-3117 could be a blockbuster
A More Complete Update can be found....
Juniorminingnetwork PVG
HappyBee......
Contrary to what you may believe (or have been told) I am not the only admin operating on Ihub that reviews this board. The site has it's own internal admin who review the boards and moderate as they see fit.
This is a most......."lively" board and due to that it has come under the microscope of the site admins quite regularly.
I remind all posters to be courteous to your fellow posters at all times.
People disagree, that is the spice of life. However there is a right way and a wrong way to express that opinion.
Go $SPTS GO!
Hi Spidey, Well explained (better than the first time ;)
I see where you are coming from and from what you say PLX-R18 has the whip hand on the other three, not to mention that it is NOT a drug but a human cell derived therapy. Tbh, I was just a bit shocked to see that article, given all the hopes we have for R18 and considering it is the most advanced therapy in the PSTI pipeline.
As Gary said (and I do appreciate your 'boots on the ground' outlook on the stem cell scenario), I invested and invest in this company because of my belief in what they can accomplish without concocting a 'witches brew' of compounds that may heal you today and kill you later. However, PSTI do need to get a move on with getting PLX-R18 approved and keeping us more informed on their progress in this regard. I probably would not be the only one alarmed at that article and wondering whats up with the much vaunted PLX-R18 that we are invested in. Regardless of whether we are ahead of the game or not, do you not find that the management are remiss in their updating of the people that are keeping the lights on and the factory running?
Other companies do, with much less in their pipeline(CBLI) than we have.
Nonetheless thank you for your post. It has put my mind at ease a little.
Run $PSTI Run!
I read it the first time he posted it.
I cannot dispute the facts however, the FDA know those facts also.
Why give them ODD with all that entails?
Orphan Drug Designation Granted to Potential Acute Radiation Syndrome Treatment
Not good at all!
Starting to wonder if
Let us just hope.....
That the people below know something we don't know ;)
RNN PT Raised
Saddle up Belus!
This is one of the moments we have been waiting patiently for.
GLTA
About Time :)
I have been sitting patiently waiting for this.
Notice the times of the sessions? I wonder if they are going to present whilst the main market is still open or wait for the after-market session?
Expecting some good action either way.
GLTA!!!
NEWS!!!!
One day..............
Nothing that is said will be able to, of this I am certain.
Not Long....
To wait now :)
The Market.......
Seems to have sat up and taken notice :)